Actively Recruiting

Age: 18Years +
All Genders
NCT05284877

The Organ Transplant Recipient HPV and Skin Cancer Study

Led by Merete Haedersdal · Updated on 2025-04-01

1500

Participants Needed

3

Research Sites

1094 weeks

Total Duration

On this page

Sponsors

M

Merete Haedersdal

Lead Sponsor

D

Danish Cancer Society

Collaborating Sponsor

AI-Summary

What this Trial Is About

Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers. In particular, OTRs have increased risk of skin cancer and cancers caused by human papillomavirus (HPV), including cervical cancer and oropharyngeal cancer. There is currently limited knowledge on risk factors for HPV infection and skin cancer in OTRs, and limited knowledge on the natural history of HPV infection and cervical neoplasia in OTRs compared with immunocompetent controls. With a continuously increasing number of OTRs, there is a growing need to improve our understanding of the long-term reactions to immunosuppression. The overall aim of this study is to investigate long term effects of immunosuppression on cutaneous and mucosal epithelium in Danish OTRs, including the risk of skin dysplasia and skin cancer, cervical and oral HPV infection and HPV-related dysplasia and cancer in OTRs. This study will be designed as a prospective observational cohort study based on clinical data and data from nationwide Danish registries. A total of 600 female OTRs, 300 male OTRs and 600 female controls will be included from Danish dermatology departments. The study aims to provide knowledge relevant for improving prevention of skin- and HPV-related cancers in OTRs, including personalized screening recommendations according to individual patient risk.

CONDITIONS

Official Title

The Organ Transplant Recipient HPV and Skin Cancer Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 2518 years
  • Solid organ transplantation recipients, including kidney, liver, lung, and heart transplant recipients
  • Stable immunosuppressive treatment for at least 3 months
  • No signs of acute graft rejection
  • Patients who reside in Denmark
  • Informed written consent obtained
  • Able patients aged 2518 years (for control group)
  • No known immunosuppressive therapy or condition (for control group)
  • Patients who reside in Denmark (for control group)
  • Informed written consent obtained (for control group)
Not Eligible

You will not qualify if you...

  • Patients with concomitant bone marrow transplantation
  • Full hysterectomy
  • Full hysterectomy (for control group)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Department of Dermatology, Bispebjerg Hospital

Copenhagen NV, Capital Region, Denmark, 2400

Actively Recruiting

2

Department of Dermatology and Allergy, Herlev og Gentofte Hospital

Hellerup, Capital Region, Denmark, 2900

Actively Recruiting

3

Department of Dermatology, Zealand University Hospital

Roskilde, Region Sjælland, Denmark, 4000

Actively Recruiting

Loading map...

Research Team

L

Lene Rask

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here